18F-FDG PET/CT for Response Assessment in Lung Cancer

Treatment response assessment in lung cancer is crucial in the management strategy and outcome of patients. Accurate treatment response assessment can guide the treating physi-cians and improve patient survival. Anatomic and metabolic tumor response assessments have been evaluated extensively, showing a positive impact in the management of these patients. 18F-FDG PET/CT provides early and more specific treatment response assess-ments, preceding anatomic changes in these tumors. Familiarity with the different treatment response assessment algorithms, criteria, time intervals, imaging pitfalls is essential for treating physicians and nuclear radiologists to provide accurate response assessments. Artificial Intelligence is being more frequently explored for this purpose and can assist physicians in providing prompt and accurate treatment response assessments. Semin Nucl Med 52:662-672 (c) 2022 Published by Elsevier Inc.